The pathological accumulation of abnormally hyperphosphorylated and aggregated tau, a neuronal microtubule (MT)-associated protein that functions to maintain MT stability, is implicated in a number of hereditary and sporadic neurodegenerative diseases including frontotemporal dementia and Alzheimer's disease. Targeting tau for the treatment of these diseases is an area of intense interest and toward that end, modulation of cellular molecular chaperones is a potential therapeutic target. In particular, the constitutive Hsp70 isoform, Hsc70, seems highly interconnected with tau, preserving tau protein levels and synergizing with it to assemble MTs. But the relationship between tau and Hsc70, as well as the impact of this interaction in neurons and its therapeutic implications remain unknown. Using a human dominant negative Hsc70 that resembles isoform selective inhibition of this important chaperone, we found for the first time that Hsc70 activity is required to stimulate MT assembly in cells and brain. However, surprisingly, active Hsc70 also requires active tau to regulate MT assembly in vivo, suggesting that tau acts in some ways as a co-chaperone for Hsc70 to coordinate MT assembly. This was despite tau binding to Hsc70 as substrate, as determined biochemically. Moreover, we show that while chronic Hsc70 inhibition damaged MT dynamics, intermittent treatment with a small molecule Hsp70 inhibitor lowered tau in brain tissue without disrupting MT integrity. Thus, in tauopathies, where MT injury would be detrimental to neurons, the unique relationship of tau with the Hsc70 machinery can be exploited to deplete tau levels without damaging MT networks.
Introduction
Cellular protein metabolism relies on a network of the heat shock protein (Hsp) family of chaperones whose variety of functions ensures proper proteostasis: refolding, sorting and degradation of client proteins. The vital role of these proteins in many aspects of cellular functions has led to the development of small molecule inhibitors targeting chaperones for use as anti-cancer agents (1) (2) (3) (4) and therapeutics for neurodegenerative disorders (5) (6) (7) (8) .
While molecules targeting Hsp90, the major chaperone ATPase, have been in development for more than a decade and are in advanced clinical stages, inhibitors of Hsp70, the other major ATPase chaperone family, have only recently been described and none have yet entered the clinic based on this mechanism of action. One of the reasons for this slower development of Hsp70 inhibitors has been that there are 10 isoforms in mammalian cells and selective inhibitors are currently not available (9) (10) (11) (12) (13) . Moreover, Hsp70 proteins are very promiscuous, affecting many proteins in the cell, while Hsp90 proteins are slightly more discriminating in regard to their clientele. In particular, the constitutively expressed isoform of Hsp70, Hsc70/ Hsp73/HSPA8, accounts for 2% of total protein in cells and affects a number of processes including cytoskeletal function and clathrin-mediated endocytosis (14) . Hsc70 associates with both intact MTs (15) (16) (17) (18) (19) and tubulin directly through its nucleotidebinding domain (NBD), suggesting functional regulation of tubulin by Hsc70 beyond proteostasis (20) . Hsc70 also interacts with the microtubule (MT)-associated protein (MAP) tau, a putative 'typical' client of Hsc70 (6, (21) (22) (23) further suggesting that Hsc70 uniquely regulates MT dynamics (24, 25) . In addition to its role in MT stability, abnormal tau accumulation is linked to the pathology of a number of neurodegenerative diseases including Alzheimer's disease (AD), frontotemporal dementia (FTD), Pick's disease and chronic traumatic encephalopathy (26) . Several of these tauopathies are characterized by mutations in the MAPT gene resulting in tau protein mutations that can compromise tau-mediated MT stabilization (27, 28) .
A growing body of evidence indicates that tau has a unique relationship with chaperone proteins despite its intrinsically disordered structure. For example, tau was recently shown to interact directly with Hsp90, showing for the first time how a client binds to the large Hsp90 homodimer (29) . Tau is also triaged differently by distinct Hsp70 isoforms: tau degradation is facilitated by the stress-inducible Hsp72, whereas the constitutively expressed Hsc70 stabilizes tau levels and promotes MT assembly (30) . Hsc70-mediated stabilization of tau levels may be relevant to tauopathies, as high levels of Hsc70 are found in brains of AD patients relative to other Hsp70 isoforms (30) . Compounds that inhibit Hsp90 and Hsp70 family proteins reduce tau levels (6, 11, (31) (32) (33) and rescue synaptic plasticity defects in tauopathy mouse models (33) . Based on this evidence, we sought to determine why Hsc70 and tau are so intimately involved with each other and perhaps determine the most effective way to exploit this interaction for therapeutic intervention to treat tauopathies.
Results
Our previous work showed that the primary isoform of Hsp70 that contributes to tau preservation in cells is Hsc70 (30) . We also discovered that wild-type (WT) Hsc70 and tau could synergistically stimulate MT assembly in Xenopus cell-free oocyte extracts (22) , but it remained unclear whether the enzymatic activity of Hsc70 was necessary for this mechanism and whether this relationship was relevant in vivo. We examined the effects of an engineered variant of human Hsc70 that lacks both ATPase and refolding activity (34) on MT assembly in the Xenopus system (22) . As previously shown, active, WT Hsc70 stimulated tubulin assembly (30) , but the inactive Hsc70 variant did not (Fig. 1A) , showing for the first time a clear connection between Hsc70 activity and MT assembly. When active and inactive Hsc70 were administered with recombinant WT tau to the same Xenopus extracts, tubulin polymerization was significantly increased in lysates having WT tau and active Hsc70, but not with WT tau and inactive Hsc70 (Fig. 1A) , indicating that tau cooperates with active Hsc70 to stimulate MT assembly in this cell-free system. Interestingly, active Hsc70 was unable to effectively polymerize MTs when combined with the FTD-associated P301L mutant tau (Fig. 1A) , further suggesting that these two proteins, Hsc70 and tau, are interdependent on each other's functionality to stimulate MT assembly as a machine (Fig. 1A) . These results were then confirmed using a reconstituted purified bovine tubulin polymerization assay-together, active Hsc70 and WT tau were able to assemble tubulin more efficiently than inactive Hsc70 (Fig. 1B) . These data suggest that Hsc70 activity was indeed required for it to synergize with tau to enhance MT assembly, and disease-associated tau mutations can impair this function, further suggesting a functional link between these two proteins with regard to MT dynamics.
We suspected that this could explain the evolutionary advantage of the interaction between Hsc70 and tau; that tau functions as a co-regulator with Hsc70 to control MT dynamics (35) (36) (37) . To confirm that the tau-tubulin association was enhanced by Hsc70, we performed live-cell imaging with GFP-tubulin and RFP-tau in the presence of either active or inactive Hsc70 ( Fig. 2A) . We found that live cells overexpressing GFP-tubulin and active Hsc70 contained less diffuse tubulin signal, suggesting more tubulin is assembled into MTs in cells overexpressing active Hsc70 ( Fig. 2A  and B) . Conversely, cells expressing inactive Hsc70 had much more diffuse tubulin signal ( Fig. 2A) . These results further suggested that ATPase activity was required for Hsc70-mediated regulation of MTs, even in human cells. We then sought to evaluate the importance of tau to this mechanism, as well as quantify the extent of MT bundling, a process involving tau (34) (35) (36) . We performed live-cell imaging in cells expressing active or inactive Hsc70 in the presence of WT tau over-expression or tau knockdown using small interfering RNA (siRNA) and performed a randomized tubulin morphology analysis, where cellular tubulin phenotype was classed as diffuse or bundled signal (Fig. 2B) . Then, we performed densitometry to quantify bundled MTs, using a masking step to exclude diffuse signal. Interestingly, tau knockdown significantly abrogated active Hsc70 from assembling and bundling MTs, whereas tau over-expression did not rescue the disassembly of MTs caused by inactive Hsc70 overexpression (Fig. 2B) . Tau over-expression increased active Hsc70-mediated MT bundling, an effect that was abrogated in the presence of the P301L mutant tau (Fig. 2) . We then examined the effects of WT Hsc70 on MT stabilization in neurons from both wild-type and Mapt −/− mice (tau knockout mice) to confirm the relevance of this mechanism in the brain. Expression of active Hsc70-FLAG AAV9 in WT organotypic slice cultures significantly increased axonal MT thickness compared with tau knockout slices expressing active Hsc70-AAV9 or slices from WT mice expressing GFP-AAV9 (Fig. 3 ). As expected, the inactive Hsc70 variant completely abolished any acetylated-tubulin signal (data not shown; see Fig. 3 legend), confirming that active Hsc70 requires tau to stabilize MTs, but the inactive Hsc70 takes on a dominant negative property that can disrupt MT integrity independent of tau. Collectively, these findings indicate that a hierarchy exists in the chaperone-mediated MT assembly pathway, where Hsc70 activity acts upstream of tau in controlling MT assembly and bundling, but tau is necessary for Hsc70 to regulate MT kinetics, perhaps explaining the exquisitely controlled and dynamic relationship between Hsc70 and tau. These results suggested the unexpected possibility that tau, a putative client/substrate of Hsc70, could also be working with Hsc70 to coordinate MT assembly. To further explore this possibility, we used 2D nuclear magnetic resonance spectroscopy with 15 N labeled recombinant tau and active or inactive Hsc70 to evaluate if they both bound to the same peptide motifs in tau with similar affinities. Binding specificity between either Hsc70 variant to tau was similar, with both active and inactive Hsc70 binding within the MT repeat region of tau. Thus, inhibition of Hsc70 activity does not preclude tau binding (Fig. 4A ).
To definitively determine that tau was a bona-fide client of Hsc70, we developed a fluorescence polarization assay using a LVEALY tracer, which binds specifically to the substrate-binding domain of Hsc70 with low µ affinity (Supplementary Material, peptide, which most strongly interacted with Hsc70 ( Fig. 4B ) (29, 30) , competed off the LVEALY tracer with an IC 50 of 1.60 ± 0.06 µ, while a mutant tau peptide VQPVYK did not (Fig. 4B) . Moreover, the K18 tau fragment, which spans the entire MT-binding region of tau (amino acids 246-369), was also very effective at competing off the LVEALY tracer with an IC 50 of 0.23 ± 0.06 µ, even surpassing the IC 50 of the NRLLLTG model substrate peptide (Fig. 4B) . Taken together, these data confirm that tau does bind to Hsc70 as a substrate regardless of nucleotide binding or dynamics, but tau works functionally with Hsc70 to coordinate MT assembly. Human
Since the Hsc70/tau complex is essential for proper MT control, chronic inhibition of their interaction would be detrimental to neurons. However, we hypothesized that the highly specialized relationship between tau and Hsc70 that can lead to such rapid changes in tau metabolism could ultimately be exploited in a way to avoid toxicity but still promote tau clearance. First, we examined the anti-tau efficacy and potency of a recently described rhodacyanine derivative, JG-98 (3). Indeed, this compound had superior anti-tau activity compared with other previously described Hsp70 inhibitors (Fig. 5A) (6, 11, 32, 33) . Importantly, tubulin levels were unchanged by Hsp70 inhibition. Using this new test compound, we sought to determine an Hsp70 inhibitor treatment schedule that could lower tau in neurons without affecting MT integrity. Organotypic slices from a tau transgenic mouse model were treated daily for 1 week (chronic) or twice over 1 week (intermittent) with 1 µ of JG-98. Immunofluorescence microscopy analysis show the chronic and intermittent treatment schedules both significantly reduced tau levels compared with vehicle control after 1 week (Fig. 5B) . Immunofluorescence staining for acetylated tubulin as a marker of stabilized MTs revealed that the density and extent of MT bundling was significantly reduced only in the chronically treated slices, not in the slices receiving the intermittent dosing schedule of JG-98 ( Figs 5B and 6A) . Moreover, the tau remaining in the slices treated intermittently with JG-98 was co-localized with tubulin to a similar extent as seen in control slices. These findings suggest that the remaining tau following intermittent Hsp70 inhibition was associated with MTs ( Fig. 5B) , consistent with previous findings that active chaperone proteins primarily target malfunctioning tau species that are not associated with MTs (22) . These data suggest that while Hsp70 inhibition may be deleterious for neurons using a traditional treatment strategy (i.e. once daily), intermittent or occasional dosing strategies (i.e. twice weekly) may promote the clearance of abnormal tau without affecting MT integrity.
Discussion
We show for the first time that MT dynamics are controlled by an active Hsc70/tau complex. Hsc70 must be functionally active to levels (mean ± SEM, n = 3 experiments) compared with vehicle control and acetylated-tubulin levels (mean ± SEM, n = 3 experiments). (B) Hippocampus of organotypic slices from tau transgenic mice treated chronically (daily for 5 days) or intermittently (every 2.5 days for 5 days) with vehicle or 1 µ JG-98 and immunostained for acetylated tubulin (green) and total tau (red). Nuclei are visualized by DAPI. Quantification graphs are tau intensity ± SEM, n = 3 animals and two slices per animal, eight images per slice. ***P = 0.0012 (intermittent) and ***P =< 0.0001 (chronic) by Student's t-test. Acetylated-tubulin intensity ± SEM, n = 3 animals and two slices per animal, eight images per slice. *P = 0.0316 (chronic) by Student's t-test. Scale bar is 20 µm at ×10.
promote MT assembly. However, Hsc70 required functional tau to promote MT dynamics, suggesting the novel concept that tau binds to Hsc70 as a client, but functions with Hsc70 to facilitate MT assembly, an idea supported by the fact that tau binds the substrate-binding domain of Hsc70. This newly described function may help to explain why tau is so sensitive to chaperone modulation despite its intrinsically disordered structure: Tau is used by the chaperone network to regulate MT stability (35, 36, 38, 39) . But interestingly, if tau has a disease-causing mutation, it can still interact with Hsc70, yet prevents MT assembly, adding Hsc70 as a new player to this pathogenic mechanism for tauopathy-causing mutations. This important function of the Hsc70/tau complex introduces new challenges with regard to the therapeutic potential of Hsp70 modulators for neurodegenerative diseases, particularly in the case of developing Hsc70-mediated therapeutics for use in tauopathies with known tau mutations, such as P301L, which alter tau-MT binding. However, the exquisite sensitivity of tau to Hsc70 modulation that is required for this dynamic regulation of MTs could be exploited when designing therapeutic strategies around this complex. In fact, intermittent Hsc70 inhibition in brain tissue reduced tau levels without damaging MTs. Thus, the potency of Hsp70 inhibitors against tau could be successfully exploited as a therapeutic strategy in tauopathies, but only if administered in a carefully monitored regimen which may require fine-tuning, particularly if the patient possesses a tau mutation, such as P301L, that may already have some MT deficiencies.
These findings indicate Hsc70, tau and tubulin function as a tripartite complex governed by nucleotide dynamics. For this to be the case, tau and tubulin require distinct binding sites on Hsc70. Previous reports indicate tubulin has a non-canonical binding site located near subdomain IIB in the NBD (40), and we now show that tau binds Hsc70 within the substrate-binding domain; thus, both tau and tubulin are able to interact with Hsc70 simultaneously. Tubulin assembly requires both tau and Hsc70 activity, suggesting that tubulin binding is responsive to the conformational changes in Hsc70 associated with the steps of substrate binding and nucleotide exchange (41, 42) . Together, our data propose a model wherein Hsc70 is able to bind tau both on, and as it is just disengaged, from the MT (Fig. 6B) (22) . Moreover, based on the state of MT dynamics, Hsc70 either triages tau for degradation or restores it to the MT to promote assembly. When Hsc70 activity is inhibited, the decision of tau fate is always shifted towards that of degradation, regardless of the state of the MT.
These data have further therapeutic implications beyond neurodegenerative diseases. It has been previously shown that small molecule Hsp70 inhibitors based on the MKT-077 scaffold (i.e. YM-01 and JG-98), as well as other scaffolds, are extremely effective against cancer cell lines (3,43-48) . The MKT-077-based compounds have been shown to trap all Hsp70 isoforms into an ADP bound conformer, which can disrupt a number of downstream cancer signaling pathways that regulate transactivation, cell invasion and adhesion (48) (49) (50) . Because the induction of the Hsp72 isoform in oncogenic cell lines is known to be cyto-protective, most of the mechanistic studies regarding Hsp70 inhibitors in cancer have been focused on how these compounds influence this inducible Hsp70 isoform. However, our findings now provide another mechanism through which general Hsp70 inhibitors might be effective anti-cancer agents; by inhibiting Hsc70-mediated regulation of MT stability. Indeed, compounds that alter MT dynamics are an area of extensive study and several are currently used in the clinic (51) . Moreover, recent work even implicates tau in the pathogenesis and prognosis of cancer (52) (53) (54) (55) (56) , further supporting this mechanistic link between tau, Hsc70 and MTs. Thus, while isoform selective Hsp70 inhibitors could be best suited for neurodegenerative diseases, it is possible that compounds capable of targeting multiple Hsp70 isoforms could be most advantageous for cancer treatment.
In conclusion, these data provide new insights into how a discreet Hsp70 isoform, Hsc70, can impact MT regulation through a unique interaction with its client tau. By understanding this mechanism, implementation of Hsp70-based therapeutics in neurodegenerative diseases with abnormal tau accumulation could be realized while avoiding a potential major on-target side effect. Our findings finally explain the evolutionary advantage of the chaperone interaction with the intrinsically disordered protein tau, which was a mystery until now. More broadly, these results also show that the chaperone/client interface can have a functional role in essential cellular processes beyond that of proteostasis and protein metabolism.
Materials and Methods

Reagents
Unless stated otherwise, all chemical reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).
Plasmids and antibodies
The following antibodies were purchased commercially: Hsc70 (Stressgen, Enzo Life Sciences, Farmingdale, NY, USA), tauH150 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin, acetylated tubulin, β-tubulin and M2-Flag (Sigma-Aldrich), DnaJC7, DnaJA1 and beclin-1(Abcam, Cambridge, MA, USA) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technologies, Danvers, MA, USA). The PHF1 antibody was a generous gift from Dr Peter Davies.
For mammalian expression experiments, full-length human Hsc70 was cloned into pCMV6 (Origene, Rockville, MD, USA) or pAAV9 vectors with an N-terminal flag tag to distinguish between endogenous and overexpressed isoforms. The Hsc70 E175S (inactive) mutation and P301L tau mutations were introduced via site-directed mutagenesis (Stratagene, La Jolla, CA, USA) and all sequences were verified before use. WT 4R0N tau was cloned into pCDNA3.1+ as previously described (30) . For recombinant protein preparations, active and inactive Hsc70 were cloned into the pET28a vector (Midwest Center for Structural Genomics, Bethesda, MD, USA).
Expression and purification of recombinant proteins
Wild-type 4R0N Tau, Hsc70 (active and inactive), Hsc70 SBD and Hsc70 NBD fragments, were purified as described previously (30, 57) .
Fluorescence polarization assays
Fluorescence polarization (FP) experiments using the HLA-FAM and ATP-FAM reporter were performed as described previously (57) . For the LVEALY reporter, please see Supplementary Material, Experimental Procedures.
Nuclear magnetic resonance spectroscopy 
In vitro MT assays
Microtubule assays with recombinant WT or P301L 4R0N tau and active or inactive Hsc70 in Xenoupus egg extracts were performed as described previously (30) . Purified bovine brain tubulin (generously provided by Dr Jared Cochran) was incubated at 34°C in the presence of recombinant active or inactive Hsc70 and WT 4R0N tau for 1 h and then centrifuged to pellet polymerized tubulin. Supernatants and pellets were then assayed by western blot.
Cell culture, lysis and immunoblotting
HEK293T cells were maintained and transfected as described previously (30) .
siRNA-mediated knockdown siRNAs for human MAPT were purchased from Qiagen (Buffalo Grove, IL, USA). Knockdowns were performed for 72 h on HEK293T with 40 n siRNA using silentFECT (BioRad, Hercules, CA, USA).
Ex-vivo slice cultures, transduction, drug treatment and immunofluorescent staining were fixed, permeablized and blocked as described previously (58) . Slices were incubated in the appropriate primary antibodies for 2 days followed by anti-goat Alexa-Fluor conjugated secondary antibodies (Life Technologies). Nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI) staining, then coverglass applied using ProLong antifade reagent (Life Technologies). For JG-98 treatments, 1 µ JG-98 or the equivalent amount of vehicle (DMSO) was added to the culture media of P301L tau organotypic slices at DIV5 for 6 h before returning to complete media without treatment. Slices were treated either daily (chronic) or every 2.5 days (intermittent), then processed for immunofluorescence as described earlier. Acute slice cultures from rTg4510 mice were performed as described (33) .
Microscopy and image analysis
All imaging was performed on an Olympus FV1000 MPE multiphoton laser scanning microscope. For both fixed slices and live cells, confocal z-stack images (1 µm slices) were captured using a ×10 or ×60 objective from a minimum of four fields containing at least 15-20 cells per condition over three experimental repeats. Image analysis was performed using Image J. Briefly, z-stacks were background subtracted, despeckled and thresholds set in each channel to include regions of interest. For organotypics, masking was applied to include only neurons that expressed virus. Pearson's coefficients and mean red and green intensities were calculated. Data are means of at least five cells per field and eight z-stacks each from three experimental repeats for cells and eight fields from each of two slices per animal, n = 3 animals per treatment.
For bundled tubulin imaging from live cells, only particles corresponding to bundled MTs (calculated in the vector only control condition) were analyzed for intensity by applying a minimum threshold to exclude diffuse, non-bundled signal and a masking analyses applied to avoid bright but unbundled, unincorporated tubulin signal. These thresholds were applied equally across conditions and intensity density was used to quantify bundled tubulin. Data are means of at least 10-slice z-stacks of five cells per field, eight fields per experiment. Experiments were repeated three times. Microtubule thickness was measured using the line tool in ImageJ. Colocalization was analyzed using the Colocalization Indices plugin in ImageJ.
Statistical analysis
Statistical analyses were performed by one-way ANOVA tests with Tukey's post-hoc analyses as indicated in the figure legends, using GraphPad Prism 5.0 software. In the instance of only a pairwise comparison in Figure 5 , Student's t-tests were performed.
